Active material: human placenta hydrolysate
When ATH: A05BA
CCF: Gepatoprotektor
ICD-10 codes (testimony): K70, K73
When CSF: 11.16
Manufacturer: WOUND Clinic LLC (Russia)
Solution for injection in the form of clear liquid from yellow to Brown, with a characteristic odor.
| 1 amp. | |
| human placenta hydrolysate | 112 mg |
Excipients: water d / injection, sodium hydroxide or hydrochloric acid (for pH correction).
2 мл – ампулы темного стекла (10) – пачки картонные.
2 мл – ампулы темного стекла (50) – пачки картонные.
2 мл – ампулы темного стекла (200) – пачки картонные.
Gepatoprotektor. Biologically active substances, contained in the gidrolizate, stimulate regeneration of hepatocytes, reduce the deposition of lipids and cholesterol in hepatocytes, increase the activity of tissue respiration, metabolism in the liver, reduce the intensity of the development of connective tissue in the liver.
Pharmacokinetic data not available.
-chronic liver disease: steatogepatity (alcohol, metabolic and mixed etiology).
In/m drug appoint 2 ml / day (112 mg active substance placenta hydrolysate). Depending on the severity of the disease frequency injection can be increased up to 2-3 time (to 6 ml)/d.
In/in drip drug appoint 10 ml (560 mg placenta hydrolysate) (5 ampoules), which previously dissolved in 250-500 ml 5% solution dekstrozy or physiological solution and then injected through a vein during flat 1.5-2 no. Injections are daily. A course of treatment - 2-3 of the week.
Side effects are observed at 3.7% patients.
Clinically relevant undesirable reactions: allergic reactions (incl. anaphylactic shock).
Other adverse effects: soreness at the injection site (2.56%), redness (0.37%), itchy skin (0.37%), onemenenie in injection (0.37%), gynecomastia (0.37%) – причинно-следственная связь с введением препарата не установлена.
- Children's age (there is no clinical experience with);
- Hypersensitivity to the drug.
FROM caution should be used in patients with polyvalent allergy to medications, the elderly.
IN experimental studies not detected toxic and teratogenic action of the preparation.
When conducting clinical trials is not marked side effects or any adverse events when using this drug in pregnancy and during breastfeeding vskarmlivaija.
On currently available data, the preparation may be nominated for the elderly. However, given the, What physiological functions in the elderly are deteriorating, the preparation should be applied carefully monitored.
Use in Pediatrics
Use of the drug in children and adolescents is not recommended, tk. studies on the safety of the children (including newborns and infants) not carried out.
Currently, the cases of drug overdose Laennek were reported.
Pharmaceutical interaction
When mixing a solution of Laenneka with other drugs, are strong bases (pH above 8.5), the activity of drug reduces.
So far not revealed any other clinically significant drug interaction drug.
The drug is released under the prescription.
The drug should be stored in the dark, inaccessible to children at temperature from 18 ° to 25 ° C. Shelf life - 3 year.
This site uses cookies and services to collect technical data from visitors to ensure performance and improve the quality of service.. By continuing to use our site, you automatically agree to the use of these technologies.
Read More